Standout Papers

Cardiovascular morbidity and mortality in the Losartan Intervent... 1991 2026 2002 2014 3.8k
  1. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol (2002)
    Björn Dahlöf, Richard B. Devereux et al. The Lancet
  2. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial (1999)
    Lennart Hansson, Lars Lindholm et al. The Lancet
  3. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension) (1991)
    Björn Dahlöf, L. Hansson et al. The Lancet
  4. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol (2002)
    Lars Lindholm, Hans Ibsen et al. The Lancet
  5. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study (1999)
    Lennart Hansson, Lars Lindholm et al. The Lancet
  6. Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study (2000)
    Lennart Hansson, Thomas Hedner et al. The Lancet
  7. Should β blockers remain first choice in the treatment of primary hypertension? A meta-analysis (2005)
    Lars Lindholm, Bo Carlberg et al. The Lancet
  8. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol (2005)
    Kristian Wachtell, Mika Lehto et al. Journal of the American College of Cardiology

Immediate Impact

2 by Nobel laureates 2 from Science/Nature 171 standout
Sub-graph 1 of 9

Citing Papers

PIEZOs mediate neuronal sensing of blood pressure and the baroreceptor reflex
2018 StandoutScienceNobel
A call to action and a lifecourse strategy to address the global burden of raised blood pressure on current and future generations: the Lancet Commission on hypertension
2016 Standout
163 intermediate papers

Works of Lars Lindholm being referenced

Reductions in albuminuria and in electrocardiographic left ventricular hypertrophy independently improve prognosis in hypertension: the LIFE Study
2006
Should β blockers remain first choice in the treatment of primary hypertension? A meta-analysis
2005 Standout
and 43 more

Author Peers

Author Last Decade Papers Cites
Lars Lindholm 13748 1338 1512 6417 2416 339 20.1k
Jackson T. Wright 17032 1482 1250 5665 3282 190 26.3k
Stephen MacMahon 15926 1098 1592 6831 4356 246 26.7k
Henry R. Black 17193 1120 1070 6976 3510 259 29.2k
Koon Teo 12164 1097 1284 3797 3966 374 22.2k
Raymond R. Townsend 14160 783 758 4329 3606 427 24.6k
Ulf dé Fairé 13323 1077 760 7940 4284 379 29.7k
Daniel T. Lackland 11725 1662 1791 4197 3584 262 23.4k
Franz H. Messerli 15765 282 738 5343 3092 413 22.3k
Cheryl Dennison Himmelfarb 9983 2581 1500 3509 3459 235 21.5k
Guy De Backer 11963 1944 2608 5489 7343 295 23.5k

All Works

Loading papers...

Rankless by CCL
2026